Mohammed Raja
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Mohammed Raja has a total of 101 co-authors. Here are the top co-authors by number of shared publications:
- Yoichiro Natori
Division of Infectious Disease, Department of Medicine, University of Miami Miller School of Medicine , Miami, Florida
13 shared publications - Anthony D. Anderson
Department of Pharmacy Sylvester Comprehensive Cancer Center Miami Florida USA
6 shared publications - Jose Fernando Camargo
Division of Infectious Diseases Miami Florida 33136 University of Miami Department of Medicine
5 shared publications - Michele I. Morris
Division of Infectious Diseases, University of Miami Miller School of Medicine, Miami, Florida, USA
5 shared publications Mark Goodman
Division of Transplantation and Cellular Therapy Sylvester Comprehensive Cancer Center Miami Florida USA
4 shared publications- Trent Peng Wang
Department of Medicine, Division of Transplantation and Cellular Therapy, Miller School of Medicine and Sylvester Comprehensive Cancer Center, Miami, FL 33136, USA
4 shared publications
Latest Publications
- Open Access
- 28 July 2026
- Published by Wiley in American Journal of Hematology
- Vol. 101 (10) , 2691-2695
Dasatinib Exposure and Risk of CMV Reactivation in Philadelphia Chromosome‐Positive Acute Lymphoblastic Leukemia
- 28 July 2026
- Published by Wiley in American Journal of Hematology
- Vol. 101 (10) , 2691-2695
Open AccessDasatinib Exposure and Risk of CMV Reactivation in Philadelphia Chromosome‐Positive Acute Lymphoblastic Leukemia
- 22 June 2026
- Published by Oxford University Press (OUP) in The Journal of Infectious Diseases
- Vol. 234 (4) , e1022-e1023
Viral Culture Conversion With Use of Remdesivir for Respiratory Syncytial Virus Lower Respiratory Tract Infection
- 22 June 2026
- Published by Oxford University Press (OUP) in The Journal of Infectious Diseases
- Vol. 234 (4) , e1022-e1023
Viral Culture Conversion With Use of Remdesivir for Respiratory Syncytial Virus Lower Respiratory Tract Infection
- Open Access
- 5 February 2026
- Published by Springer Nature in Mycopathologia
- Vol. 191 (2) , 29
Clinical Characteristics and Outcomes of Invasive Aspergillosis in Patients with Hematological Malignancies and Transplantation and Cellular Therapies in the Contemporary Era
Background: Despite important advancements in diagnostic modalities, routine use of therapeutic drug monitoring (TDM) and newer antifungal therapies, there is a paucity of contemporary data regarding clinical characteristics and outcomes of invasive aspergillosis (IA) in the United States. Methods: Single-center, retrospective cohort study of hospitalized patients between 2015 and 2020, who had active hematological malignancy (HM) or had undergone transplantation and cellular therapy (TCT) and had probable or proven IA. Results: Sixty-two patients with probable or proven IA, including 21 HM and 41 TCT, were identified. Forty-four percent of the cases corresponded to breakthrough IA. Bronchoalveolar lavage galactomannan was ≥ 1 in 71% and ≥ 0.5 in 88%, while serum galactomannan was ≥ 0.5 in only 34%. Among assessable patients (n = 59), 90-day partial or complete response to antifungal therapy occurred in 39%. All-cause mortality for the entire cohort was 22% at 30 days and 46% at 90 days. IA attributable mortality was 18% at 30 days and 38% at 90 days. Achieving therapeutic antifungal serum levels was associated with a reduction in all-cause mortality, while prior clinically significant CMV infection (aOR 9.65, 95% CI 1.34–69.6; P = 0.025) and relapsed/refractory hematological disease (aOR 8.5, 95% CI 2.23, 32.4; P = 0.002) were associated with higher IA attributable mortality. Conclusions: Despite advancements in diagnosis and treatment, IA remains associated with poor outcomes in hematological patients in the contemporary era. Newer antifungals and improved strategies for monitoring and prevention of IA in these vulnerable patient populations are urgently needed.
- 5 February 2026
- Published by Springer Nature in Mycopathologia
- Vol. 191 (2) , 29
Open AccessClinical Characteristics and Outcomes of Invasive Aspergillosis in Patients with Hematological Malignancies and Transplantation and Cellular Therapies in the Contemporary Era
Background: Despite important advancements in diagnostic modalities, routine use of therapeutic drug monitoring (TDM) and newer antifungal therapies, there is a paucity of contemporary data regarding clinical characteristics and outcomes of invasive aspergillosis (IA) in the United States. Methods: Single-center, retrospective cohort study of hospitalized patients between 2015 and 2020, who had active hematological malignancy (HM) or had undergone transplantation and cellular therapy (TCT) and had probable or proven IA. Results: Sixty-two patients with probable or proven IA, including 21 HM and 41 TCT, were identified. Forty-four percent of the cases corresponded to breakthrough IA. Bronchoalveolar lavage galactomannan was ≥ 1 in 71% and ≥ 0.5 in 88%, while serum galactomannan was ≥ 0.5 in only 34%. Among assessable patients (n = 59), 90-day partial or complete response to antifungal therapy occurred in 39%. All-cause mortality for the entire cohort was 22% at 30 days and 46% at 90 days. IA attributable mortality was 18% at 30 days and 38% at 90 days. Achieving therapeutic antifungal serum levels was associated with a reduction in all-cause mortality, while prior clinically significant CMV infection (aOR 9.65, 95% CI 1.34–69.6; P = 0.025) and relapsed/refractory hematological disease (aOR 8.5, 95% CI 2.23, 32.4; P = 0.002) were associated with higher IA attributable mortality. Conclusions: Despite advancements in diagnosis and treatment, IA remains associated with poor outcomes in hematological patients in the contemporary era. Newer antifungals and improved strategies for monitoring and prevention of IA in these vulnerable patient populations are urgently needed.
- 19 May 2025
- Published by Elsevier in The Journal of Heart and Lung Transplantation
- Vol. 44 (6) , 1007-1008
Maribavir: Double edged sword
- 19 May 2025
- Published by Elsevier in The Journal of Heart and Lung Transplantation
- Vol. 44 (6) , 1007-1008
Maribavir: Double edged sword
- Open Access
- 14 March 2025
- Published by Oxford University Press (OUP) in Open Forum Infectious Diseases
- Vol. 12 (4) , ofaf163
Incidence of Breakthrough Fungal Infections in Patients With Isavuconazole Prophylaxis: A Systematic Review and Meta-analysis
Background: Isavuconazole (ISA) is a newer triazole that has activity against most mold species and has been utilized for prophylaxis as well as treatment in patients with hematologic malignancies (HM) and hematopoietic stem cell transplant (HSCT). However, several studies have documented breakthrough invasive fungal infections (bIFIs). Thus, we conducted a systematic review and meta-analysis to investigate the incidence of bIFIs among patients receiving ISA prophylaxis. Methods: We conducted a systematic review and meta-analysis of the published literature using the concept of ISA, HSCT, and HM from 5 search engines. In patients with HSCT and HM, the pooled incidence of bIFI while undergoing ISA prophylaxis was calculated via the DerSimonian-Laird random effect model. Results: The systematic review and meta-analysis included 35 and 19 studies, respectively. In total, 991 patients were identified as using ISA prophylaxis, and the majority had either acute myeloid leukemia or myelodysplastic syndrome (69.9%). The pooled incidence of proven/probable bIFI was 7% (95% CI, 4%–12%, I2 = 55%). The most common pathogen was Aspergillus species (43.1%), followed by Candida (22.4%) and Mucorales (12.1%). In 19 studies, mortality rates were documented and ranged between 0% and 100%; the majority of which were >50%. Conclusions: In patients with HM or HSCT, we found a high incidence of bIFI while undergoing ISA prophylaxis, with high mortality. Given the lack of randomized clinical trials evaluating ISA in this indication, its role in prophylaxis remains unclear.
- 14 March 2025
- Published by Oxford University Press (OUP) in Open Forum Infectious Diseases
- Vol. 12 (4) , ofaf163
Open AccessIncidence of Breakthrough Fungal Infections in Patients With Isavuconazole Prophylaxis: A Systematic Review and Meta-analysis
Background: Isavuconazole (ISA) is a newer triazole that has activity against most mold species and has been utilized for prophylaxis as well as treatment in patients with hematologic malignancies (HM) and hematopoietic stem cell transplant (HSCT). However, several studies have documented breakthrough invasive fungal infections (bIFIs). Thus, we conducted a systematic review and meta-analysis to investigate the incidence of bIFIs among patients receiving ISA prophylaxis. Methods: We conducted a systematic review and meta-analysis of the published literature using the concept of ISA, HSCT, and HM from 5 search engines. In patients with HSCT and HM, the pooled incidence of bIFI while undergoing ISA prophylaxis was calculated via the DerSimonian-Laird random effect model. Results: The systematic review and meta-analysis included 35 and 19 studies, respectively. In total, 991 patients were identified as using ISA prophylaxis, and the majority had either acute myeloid leukemia or myelodysplastic syndrome (69.9%). The pooled incidence of proven/probable bIFI was 7% (95% CI, 4%–12%, I2 = 55%). The most common pathogen was Aspergillus species (43.1%), followed by Candida (22.4%) and Mucorales (12.1%). In 19 studies, mortality rates were documented and ranged between 0% and 100%; the majority of which were >50%. Conclusions: In patients with HM or HSCT, we found a high incidence of bIFI while undergoing ISA prophylaxis, with high mortality. Given the lack of randomized clinical trials evaluating ISA in this indication, its role in prophylaxis remains unclear.
- Open Access
- 5 October 2024
- Published by Elsevier in American Journal of Ophthalmology Case Reports
- Vol. 36, 102183
To do or not to do: Large-dose steroid treatment for severe vision loss secondary to compressive inflammatory optic neuropathy in the setting of invasive fungal sinusitis
- 5 October 2024
- Published by Elsevier in American Journal of Ophthalmology Case Reports
- Vol. 36, 102183
Open AccessTo do or not to do: Large-dose steroid treatment for severe vision loss secondary to compressive inflammatory optic neuropathy in the setting of invasive fungal sinusitis
- Open Access
- 12 July 2024
- Published by American Society of Hematology in Blood Advances
- Vol. 8 (14) , 3813-3822
Incidence and outcomes of cytomegalovirus reactivation after chimeric antigen receptor T-cell therapy
Cytomegalovirus (CMV) reactivation is a major complication among seropositive allogeneic hematopoietic cell transplantation recipients; however, data on CMV reactivation after chimeric antigen receptor (CAR) T-cell therapy are limited. We report the incidence and outcomes of 95 adult CMV-seropositive patients who received CAR T-cell therapy between February 2018 and February 2023. CMV outcomes were CMV reactivation (any viremia) and clinically significant CMV infection (cs-CMV). Thirty-one patients (33%) had evidence of CMV reactivation (any viremia), and 10 patients (11%) had cs-CMV. The median time from CAR T-cell infusion to CMV reactivation was 19 days (interquartile range [IQR], 9-31). The cumulative incidence of CMV (any viremia) was significantly higher among patients with grade 3 to 4 cytokine release syndrome (67 vs 28%; P = .01), and those who received corticosteroids (39 vs 21%; P = .03), anakinra (56 vs 28%; P = .02), or ≥2 immunosuppressants (41 vs 21%; P = .02). Receipt of corticosteroids (18 vs 0%; P = .004), tocilizumab (14 vs 0%; P = .04), anakinra (33 vs 7%; P = .008), and ≥2 immunosuppressants (20 vs 0%; P = .001) were all associated with cs-CMV. Receiving ≥2 immunosuppressants was associated with a twofold increase in CMV reactivation in multivariate analyses (adjusted odds ratio [aOR], 2.27; 95% confidence interval, 1.1-4.8; P = .03). Overall, the 1-year mortality was significantly higher in those with CMV reactivation (57% vs 23%; P = .001). Immunosuppression, particularly with corticosteroids, for the management of CAR T-cell toxicities, is a major risk factor for CMV reactivation.
- 12 July 2024
- Published by American Society of Hematology in Blood Advances
- Vol. 8 (14) , 3813-3822
Open AccessIncidence and outcomes of cytomegalovirus reactivation after chimeric antigen receptor T-cell therapy
Cytomegalovirus (CMV) reactivation is a major complication among seropositive allogeneic hematopoietic cell transplantation recipients; however, data on CMV reactivation after chimeric antigen receptor (CAR) T-cell therapy are limited. We report the incidence and outcomes of 95 adult CMV-seropositive patients who received CAR T-cell therapy between February 2018 and February 2023. CMV outcomes were CMV reactivation (any viremia) and clinically significant CMV infection (cs-CMV). Thirty-one patients (33%) had evidence of CMV reactivation (any viremia), and 10 patients (11%) had cs-CMV. The median time from CAR T-cell infusion to CMV reactivation was 19 days (interquartile range [IQR], 9-31). The cumulative incidence of CMV (any viremia) was significantly higher among patients with grade 3 to 4 cytokine release syndrome (67 vs 28%; P = .01), and those who received corticosteroids (39 vs 21%; P = .03), anakinra (56 vs 28%; P = .02), or ≥2 immunosuppressants (41 vs 21%; P = .02). Receipt of corticosteroids (18 vs 0%; P = .004), tocilizumab (14 vs 0%; P = .04), anakinra (33 vs 7%; P = .008), and ≥2 immunosuppressants (20 vs 0%; P = .001) were all associated with cs-CMV. Receiving ≥2 immunosuppressants was associated with a twofold increase in CMV reactivation in multivariate analyses (adjusted odds ratio [aOR], 2.27; 95% confidence interval, 1.1-4.8; P = .03). Overall, the 1-year mortality was significantly higher in those with CMV reactivation (57% vs 23%; P = .001). Immunosuppression, particularly with corticosteroids, for the management of CAR T-cell toxicities, is a major risk factor for CMV reactivation.
- Open Access
- 27 November 2023
- Published by Oxford University Press (OUP) in Open Forum Infectious Diseases
- Vol. 10 (Supplement)
463. Immunogenicity and Safety of mRNA-based SARS-CoV-2 vaccination in Hematopoietic Stem Cell Transplant Recipients: A Systematic Review
Immunization is an effective strategy to decrease hospitalization and mortality related to SARS-CoV-2. Since the introduction of mRNA-based SARS-CoV-2 vaccines (BNT1261b2 and mRNA-1273), several studies have outlined the immunogenicity and safety of these in hematopoietic stem cell transplant (HSCT) recipients. Herein, we describe the first systematic review and meta-analysis with pooled data of available evidence on SARS-CoV-2 vaccination in this patient population. We conducted a systematic review and meta-analysis of prospective cohort studies up to May 24 2022 in adult HSCT recipients who were vaccinated with ≥1 doses of either mRNA-based SARS-CoV-2 vaccine. The outcomes measured included: a) vaccine immunogenicity, b) safety, and c) breakthrough SARS-CoV-2 infections. Patients with solid organ transplant or prior documented history of SARS-CoV-2 infection were excluded. Pooled incidence of antibody positivity after one or more doses of mRNA-based SARS-CoV-2 vaccination in HSCT recipients mRNA-based SARS-CoV-2 vaccination was immunogenic in HSCT recipients, particularly among Auto-HSCT recipients. One or more doses of mRNA-based vaccine elicited a greater humoral response, compared to that of cellular immunity. Adverse events were common, but often were mild. Breakthrough infections are rare after ≥ 1 doses. John M. Reynolds, MLIS, Pfizer Inc: Stocks/Bonds
- 27 November 2023
- Published by Oxford University Press (OUP) in Open Forum Infectious Diseases
- Vol. 10 (Supplement)
Open Access463. Immunogenicity and Safety of mRNA-based SARS-CoV-2 vaccination in Hematopoietic Stem Cell Transplant Recipients: A Systematic Review
Immunization is an effective strategy to decrease hospitalization and mortality related to SARS-CoV-2. Since the introduction of mRNA-based SARS-CoV-2 vaccines (BNT1261b2 and mRNA-1273), several studies have outlined the immunogenicity and safety of these in hematopoietic stem cell transplant (HSCT) recipients. Herein, we describe the first systematic review and meta-analysis with pooled data of available evidence on SARS-CoV-2 vaccination in this patient population. We conducted a systematic review and meta-analysis of prospective cohort studies up to May 24 2022 in adult HSCT recipients who were vaccinated with ≥1 doses of either mRNA-based SARS-CoV-2 vaccine. The outcomes measured included: a) vaccine immunogenicity, b) safety, and c) breakthrough SARS-CoV-2 infections. Patients with solid organ transplant or prior documented history of SARS-CoV-2 infection were excluded. Pooled incidence of antibody positivity after one or more doses of mRNA-based SARS-CoV-2 vaccination in HSCT recipients mRNA-based SARS-CoV-2 vaccination was immunogenic in HSCT recipients, particularly among Auto-HSCT recipients. One or more doses of mRNA-based vaccine elicited a greater humoral response, compared to that of cellular immunity. Adverse events were common, but often were mild. Breakthrough infections are rare after ≥ 1 doses. John M. Reynolds, MLIS, Pfizer Inc: Stocks/Bonds
- 15 May 2023
- Published by Springer Nature in Annals of Hematology
- Vol. 102 (8) , 2283-2284
Emergence of maribavir resistance after CMV treatment in hematopoietic stem cell transplant recipient
- 15 May 2023
- Published by Springer Nature in Annals of Hematology
- Vol. 102 (8) , 2283-2284
Emergence of maribavir resistance after CMV treatment in hematopoietic stem cell transplant recipient
- 7 March 2023
- Published by Wiley in Transplant Infectious Disease
- Vol. 25 (2) , e14043
Successful restoration of protective immunity against measles, mumps, and rubella following MMR vaccination in adult hematopoietic cell transplant recipients
Background: The optimal number of doses as well as the role for measurement of postvaccination titers after measles, mumps, rubella (MMR) vaccination in adult hematopoietic cell transplantation (HCT) recipients remains unknown.Methods: In the present study, we assessed humoral immunity against measles, mumps and rubella before and after MMR vaccination in 187 adults who received at least one dose of the MMR vaccine after HCT.Results: Among those with baseline titers, posttransplant prevaccination seroprotection rates were 56%, 30%, and 54% for measles, mumps, and rubella, respectively; and significantly lower in allogeneic versus autologous HCT recipients for measles (39% vs. 80%, p = .0001), mumps (22% vs. 41%; p = .02) and rubella (48% vs. 62%, p = .12). Among those who were seronegative at baseline, seroconversion rates after one dose of MMR were 69%, 56%, and 97% for measles, mumps, and rubella, respectively. Seronegative patients after one dose of MMR (i.e., nonresponders) seroconverted for measles and mumps after a second MMR vaccine dose.Conclusion: Our findings demonstrate successful restoration of protective immunity against measles, mumps, and rubella after vaccination in adult HCT recipients; one dose of MMR elicited protective titers in the majority of patients, and a second vaccine dose was immunogenic in nonresponders. image
- 7 March 2023
- Published by Wiley in Transplant Infectious Disease
- Vol. 25 (2) , e14043
Successful restoration of protective immunity against measles, mumps, and rubella following MMR vaccination in adult hematopoietic cell transplant recipients
Background: The optimal number of doses as well as the role for measurement of postvaccination titers after measles, mumps, rubella (MMR) vaccination in adult hematopoietic cell transplantation (HCT) recipients remains unknown.Methods: In the present study, we assessed humoral immunity against measles, mumps and rubella before and after MMR vaccination in 187 adults who received at least one dose of the MMR vaccine after HCT.Results: Among those with baseline titers, posttransplant prevaccination seroprotection rates were 56%, 30%, and 54% for measles, mumps, and rubella, respectively; and significantly lower in allogeneic versus autologous HCT recipients for measles (39% vs. 80%, p = .0001), mumps (22% vs. 41%; p = .02) and rubella (48% vs. 62%, p = .12). Among those who were seronegative at baseline, seroconversion rates after one dose of MMR were 69%, 56%, and 97% for measles, mumps, and rubella, respectively. Seronegative patients after one dose of MMR (i.e., nonresponders) seroconverted for measles and mumps after a second MMR vaccine dose.Conclusion: Our findings demonstrate successful restoration of protective immunity against measles, mumps, and rubella after vaccination in adult HCT recipients; one dose of MMR elicited protective titers in the majority of patients, and a second vaccine dose was immunogenic in nonresponders. image